Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
Vaxcyte Q3 EPS $(1.99) Beats $(2.12) Estimate
Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?
Vaxcyte: Vaccine Titan In The Making
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes
Why Vaxcyte (PCVX) Is Getting Attention Again
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%)
Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial
Vaxcyte stock falls on $1B dual offering launch
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case
Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck
Vaxcyte Soars 36% on Phase 3 Pneumococcal Vaccine Win That “Sets a New Benchmark”
Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority
Vaxcyte shares surge on late-stage vaccine trial success
Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study
Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.